2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original Research
2016
Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging
Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016, 10: 4209-4218. PMID: 26967254, PMCID: PMC5257033, DOI: 10.1021/acsnano.5b07573.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDecanoic AcidsDrug Delivery SystemsEthanolaminesFemaleGenetic TherapyHeterograftsHumansMatrix Metalloproteinase 2MiceMice, Inbred C57BLNanoparticlesOptical ImagingPaclitaxelPermeabilityPolymersPurinesPyrazolesScorpion VenomsTranscytosisTumor MicroenvironmentConceptsBlood-brain barrierLow delivery efficiencyTransport of nanoparticlesCancer gene therapyNanoparticle deliveryMore nanoparticlesBrain tumorsNanoparticlesDelivery efficiencyGene therapySystemic deliveryNPsBrain malignanciesBBB modulatorsPharmacological agentsBrain cancerBrain regionsTumorsDeliveryBrainImproved treatmentInadequate amountsPositive feedback loopChemotherapyMalignancy
2013
Clinical Presentation in Diffuse Low-Grade Gliomas
Torres-Reveron J, Piepmeier J, Becker K. Clinical Presentation in Diffuse Low-Grade Gliomas. 2013, 179-188. DOI: 10.1007/978-1-4471-2213-5_12.Peer-Reviewed Original ResearchDiffuse low-grade gliomasLow-grade gliomasCommon presenting symptomHigh-grade lesionsPrimary brain tumorsStandard imaging modalityPresenting symptomHistopathological findingsClinical presentationTumor sizeNeurological syndromeAnaplastic transformationBrain tumorsMultimodal evaluationConventional imaging technologiesImaging modalitiesActive investigationTumorsGliomasNew advancesSeizuresSyndromeLesionsSymptomsGenomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Grady C, Tanrıkulu B, Bakırcıoğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kılıç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339: 1077-1080. PMID: 23348505, PMCID: PMC4808587, DOI: 10.1126/science.1233009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsChromosomes, Human, Pair 22DNA Mutational AnalysisFemaleGenes, Neurofibromatosis 2Genomic InstabilityGenomicsHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMeningeal NeoplasmsMeningiomaMiddle AgedMutationNeoplasm GradingProto-Oncogene Proteins c-aktReceptors, G-Protein-CoupledSmoothened ReceptorTumor Necrosis Factor Receptor-Associated Peptides and Proteins
2012
Role of Neurosurgery and Radiation Therapy in the Management of Brain Tumors
Patel TR, Yu JB, Piepmeier JM. Role of Neurosurgery and Radiation Therapy in the Management of Brain Tumors. Hematology/Oncology Clinics Of North America 2012, 26: 757-777. PMID: 22794282, DOI: 10.1016/j.hoc.2012.04.001.Peer-Reviewed Original Research
2009
Anaplastic oligoastrocytoma in Turcot syndrome
Baehring J, Hui P, Piepmeier J, Bannykh SI. Anaplastic oligoastrocytoma in Turcot syndrome. Journal Of Neuro-Oncology 2009, 95: 293-298. PMID: 19495563, DOI: 10.1007/s11060-009-9928-y.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenosine TriphosphatasesAgedAstrocytomaColorectal Neoplasms, Hereditary NonpolyposisDNA Repair EnzymesDNA, NeoplasmDNA-Binding ProteinsFemaleHumansImmunoenzyme TechniquesMagnetic Resonance ImagingMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinNuclear ProteinsPedigreePolymerase Chain ReactionConceptsHereditary non-polyposis colorectal cancerTurcot syndromeAnaplastic oligoastrocytomaNon-polyposis colorectal cancerYear old womanHandful of casesColorectal cancerLarge bowelDNA mismatch repair systemOlder womenBrain tumorsTumor DNABody sitesFamilial clusteringGermline mutationsRare variantsSyndromeOligoastrocytomasCancerMismatch repair systemChance occurrenceDetailed molecular dataBowelPathogenesisTumors
2006
New methods for direct delivery of chemotherapy for treating brain tumors.
Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. The Yale Journal Of Biology And Medicine 2006, 79: 141-52. PMID: 17940624, PMCID: PMC1994797.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryBrain tumorsPrimary malignant brain tumorLocal deliveryBlood-brain barrierMalignant brain tumorsStandard chemotherapeutic drugsBrain cancer treatmentAnti-cancer therapyMedian survivalInfusion siteSevere formMalignant cellsNew delivery strategiesChemotherapy drugsChemotherapyDiagnostic imagingTumorsChemotherapeutic drugsCancer treatmentDrugsInvasive cellsSource of drugsDelivery strategiesBrain
2005
Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas
Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas. Cancer Research 2005, 65: 6726-6733. PMID: 16061654, DOI: 10.1158/0008-5472.can-05-0585.Peer-Reviewed Original ResearchConceptsBEHAB/brevicanHigh-grade gliomasMalignant gliomasBrain tumorsNew potential therapeutic targetsPrimary brain tumorsNormal adult brainDeadly brain tumorCentral nervous systemPotential therapeutic targetLow-grade gliomasHuman malignant gliomasNew therapeutic strategiesPathologic courseSimilar histologyBenign gliomasAdult brainTherapeutic strategiesDiffuse invasionTherapeutic targetGlioma progressionNervous systemInvasive abilityBrain tissueGliomas
2004
Surgical Resection for Patients with Benign Primary Brain Tumors and Low Grade Gliomas
Piepmeier J, Baehring JM. Surgical Resection for Patients with Benign Primary Brain Tumors and Low Grade Gliomas. Journal Of Neuro-Oncology 2004, 69: 55-65. PMID: 15527080, DOI: 10.1023/b:neon.0000041871.46785.53.Peer-Reviewed Original ResearchConceptsPrimary brain tumorsBrain tumorsNeuroepithelial tumorsBenign primary brain tumorsMajority of patientsAdverse treatment effectsBenefits of therapyLow-grade tumorsLow-grade gliomasSurgical resectionInitial diagnosisMalignant degenerationPrimary neoplasmsSurgical managementSeizure focusBrain parenchymaChordoid gliomaNeurosurgical interventionThird ventricleChoroid plexusGrade gliomasTumorsUnknown originHeterogeneous groupCell pool
1998
Manganese-metalloporphyrin (ATN-10) as a Tumor-localizing Agent: Magnetic Resonance Imaging and Inductively Coupled Plasma Atomic Emission Spectroscopy Study with Experimental Brain Tumors
Piepmeier J. Manganese-metalloporphyrin (ATN-10) as a Tumor-localizing Agent: Magnetic Resonance Imaging and Inductively Coupled Plasma Atomic Emission Spectroscopy Study with Experimental Brain Tumors. Neurosurgery 1998, 42: 1337-1337. DOI: 10.1097/00006123-199806000-00084.Peer-Reviewed Original Research
1996
In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor.
Piepmeier J, Rabidou N, Schold S, Bitonti A, Prakash N, Bush T. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Research 1996, 56: 359-61. PMID: 8542592.Peer-Reviewed Original ResearchConceptsMalignant brain tumorsMedian survivalControl animalsAthymic miceBrain tumorsReductase inhibitorsHuman malignant brain tumorsHuman glioblastomaDays of treatmentSK-N-MCConcentration-dependent inhibitionTumor regressionIntracerebral implantsIntracerebral xenograftsXenograft modelGlioblastoma cell linesVivo inhibitionPotent antiproliferative activityNeuroblastomaGlioblastomaSurvivalCell linesXenograftsNanomolar concentrationsTumors
1983
Intracranial Adenocystic Carcinoma Presenting as a Primary Brain Tumor
Piepmeier J, Virapongse C, Kier L, Kim J, Greenberg A. Intracranial Adenocystic Carcinoma Presenting as a Primary Brain Tumor. Neurosurgery 1983, 12: 348-352. PMID: 6302554, DOI: 10.1227/00006123-198303000-00021.Peer-Reviewed Original ResearchIntracranial Adenocystic Carcinoma Presenting as a Primary Brain Tumor.
Piepmeier J, Virapongse C, Kier L, Kim J, Greenberg A. Intracranial Adenocystic Carcinoma Presenting as a Primary Brain Tumor. Neurosurgery 1983, 12: 348. DOI: 10.1097/00006123-198303000-00021.Peer-Reviewed Original Research